Navigation Links
Study identifies potential new strategy to improve odds of corneal transplant acceptance
Date:12/30/2013

DALLAS Dec. 30, 2013 For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

In the study, researchers found that corneal transplants in mice were accepted 90 percent of the time when the action of an immune system molecule called interferon-gamma (IFN-γ) was blocked and when the mice shared the same major histocompatibility complex (MHC) genotype as the donor cornea. MHC matching is not typically done with human corneal transplants because of a high acceptance rate.

"Our findings indicate that neither MHC matching alone nor administration of anti-IFN-γ antibody alone enhances graft survival. However, we found that when MHC matching is combined with anti-IFN-γ therapy, long-term corneal transplant survival is almost guaranteed," said Dr. Jerry Niederkorn, Professor of Ophthalmology and Microbiology at UT Southwestern and senior author of the study.

The study findings, reported in the December issue of the American Journal of Transplantation, suggest an option to improve the odds of a subsequent corneal transplant's success for those patients whose first transplant was rejected.

More than 40,000 corneal transplants are performed annually in the United States, making this surgical procedure one of the most common and successful in transplantation. But out of that total, about 4,000 fail, with the recipient's body rejecting the corneal graft and requiring a second operation.

A surprising finding of the study was learning that IFN-γ can act both as an immune system suppressor or activator, depending on the context of the histocompatibility antigens perceived by the immune system, Dr. Niederkorn said. Earlier studies indicated that this molecule only activated i
'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. New study: High mortality in Central Southern states most likely due to smoking
2. Contract Research Organization WCCT Global Announces Milestone for Clinical Study Completion
3. As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Finding that Acetaminophen Combined With Alcohol May Increase Risk for Kidney Damage
4. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Notes Publication of New Study Questioning Cost, Benefits of Robotic Surgery
5. PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
6. Study shows value of calcium scan in predicting heart attack, stroke among those considered at risk
7. Embargoed study: New quality, payment initiative positively impacts pediatric care
8. PM2.5 Monitor Industry in Global and China Regions 2013 Analysis in a New Study at DeepResearchReports.com
9. Austin Doctor Participates in Flu Vaccine Research Study in an Effort to Find More Effective Vaccines.
10. UV Technologies, LLC, Makers of UV-Aid® Release Results of Study Showing Photo-Oxidation Technology Highly Effective in Preventing Colds, Flu, and Ear Infections
11. Agein Corporation, a Leading Anti-Aging Company, Responds to Study Showing Personal Care Products a Possible Source of Harmful Parabens for Babies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study identifies potential new strategy to improve odds of corneal transplant acceptance
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... naturopathic and allopathic medicine, opens its second location this week at 31542 S. ... 1000 square feet of lounge space for patients to relax while receiving safe ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and educator in ... Associate Director of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where ... Boot Camps. She serves as a CDI subject matter expert for a variety of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Administrators is taking action after seeing a significant increase in unlawful tactics ... Review division has found many cases of OON ASCs encouraging members to have ...
(Date:9/2/2015)... ... 2015 , ... The 2015 China Overseas Investment and Entrepreneurship ... conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai State ... feature leading EB-5 industry professionals and Chinese private equity partners looking for international ...
Breaking Medicine News(10 mins):Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2
... KNOXVILLE, Tenn.--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced preliminary results ... the treatment of metastatic melanoma, the most aggressive form ... efficacy and bystander effect on melanoma tumors in stage ... Provecta in a total of 20 subjects at two ...
... infectious diseases and developing preventive vaccines is the ability ... response over time. An Emory-led team of scientists has ... are able to evade the immune response. The ... of the National Academy of Sciences. , Using a ...
... (TB) experts at Johns Hopkins and in Brazil have ... of drugs used to treat the highly contagious form ... to cure the illness from six months to four. ... antibiotics increased by 17 percent the number of patients ...
... survey [1] analysing how cancer research is funded ,shows ... contributor to the global ,cancer research effort. , Prof ... Forum (ECRM), launched the organisations second survey, which looks ... 2004, at the European Parliament today (Tuesday 18 September). ...
... a Year, TAMPA, Fla., Sept. 18 In response ... a two-week coma with a craving for The,Melting Pot, the ... The Melting Pot will fly Jill Finley and her family ... at its annual,meeting. On May 26, Finley,s husband Ryan ...
... College of Medicine of Yeshiva University has been awarded a ... of Health to further the medical schools study of centenarians ... Nir Barzilai, director of Einsteins Institute for Aging Research, the ... genes that appear to contribute to exceptional longevity in humans, ...
Cached Medicine News:Health News:Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study 2Health News:Chronic infection persists by targeting stromal cell network in lymphoid organs 2Health News:New antibiotic drug combo to speed up treatment of tuberculosis 2Health News:New antibiotic drug combo to speed up treatment of tuberculosis 3Health News:New antibiotic drug combo to speed up treatment of tuberculosis 4Health News:Launch of second European Cancer Research Funding survey 2Health News:Launch of second European Cancer Research Funding survey 3Health News:Launch of second European Cancer Research Funding survey 4Health News:Update on Jill Finley Story, Coma Survivor 2Health News:NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity 2
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) ... Device Studies: Clinical Evidence (London, UK - November ... This course has been designed specifically ... evidence required for medical devices and in-vitro diagnostic ... devices and the emphasis on high quality, appropriate ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. ... Coughlin , Chief Financial Officer of Neurocrine Biosciences, will ... New York City . ... at 11:25am ET (8:25am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. Advances in understanding of ... new avenues and possibilities for improved drug delivery ... enzymes, and receptors that control the penetration of ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... PSTX) today announced that The Mount Sinai Hospital in New York City has implemented its Safety-Sponge System. , ... , , ... ... ...
... N.J. , March 15 Regado Biosciences, Inc., ... with active control agents, announced that Chris Rusconi , ... Zelenkofske , DO, FACC, Senior Vice President , Chief Medical ... on Monday, March 15, 2010 in Atlanta, ...
Cached Medicine Technology:Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 2Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: